



Study of Serologic Response Rate to *Haemophilus influenzae* Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016

Reza Arjmand¹, Mehri Gholami², Fariba Shirvani^{3,*}, Omid Safari¹, Mostafa Qorbani⁴ and Mohammad Javad Gharavi⁵

¹Department of Pediatric, Shahid Bahonar Hospital, Alborz University of Medical Sciences, Karaj, Iran

²Alborz University of Medical Sciences, Karaj, Iran

³Pediatric Infectious Diseases Research Center (PIRC), Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Department of Community Medicine, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran

⁵Department of Parasitology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

*Corresponding author: Pediatric Infections Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +98-2122226941, Email: shirvanifariba@rocketmail.com

Received 2017 August 02; Revised 2018 March 09; Accepted 2018 April 08.

Abstract

Background: Hib conjugate vaccine has led to more than 90% decline in the prevalence of severe Hib diseases in countries with universal coverage vaccination program. After the addition of Hib vaccine to the national vaccination program with 3P (three doses of 2, 4, and 6 months) in IR Iran, we decided to study the vaccine efficacy after the last dose of vaccine in Iranian children in 2016.

Methods: 500 blood samples were collected from one-year-old children who referred to the health care centers in Karaj. Demographic information was gathered by a questionnaire. Blood samples were sent to a laboratory for antibody titer determination by ELISA method.

Results: 41.2% of the children (95% CI: 36.89 - 45.51) had a titre of IgG against Hib (0.15 to 1 µg/mL) (short-term protection) and 57.4% of the children had a titre of IgG against Hib (95% CI: 53.07 - 61.73) equal to or greater than 1 µg/mL (long-term protection). Antibody GMT was 6.92 µg/mL (95% CI: 6.76 - 7.08). There was no significant correlation between the titer of *H. influenzae* antibody and demographic factors.

Conclusions: In spite of the acceptable GMT titer, children who had antibody titer of < 1 µg/mL comprised approximately 40% of the study population, showing the necessity of further investigation to assess the need for H.flu booster administration.

Keywords: Serologic Response, *Haemophilus influenzae* Type B, Child

1. Background

Haemophilus influenzae type B (Hib) is an invasive organism that causes meningitis and pneumonia in children under five years of age. Before the worldwide expansion of HIB vaccination in 2000, the World Health Organization (WHO) recognized Hib responsible for more than 8 million serious infections (such as meningitis and severe pneumonia) with 38000-70000 worldwide yearly deaths in 1-59-month-old children (1-4).

The WHO introduced *Haemophilus influenzae* vaccine in the routine vaccination program for children all over the world (5). By the end of 2015, this vaccine was introduced in 191 countries. The global coverage of three doses of Hib vaccine is approximated to 64%. Nevertheless, a great varia-

tion exists between different regions (6). Before the implementation of Hib vaccination in IR Iran, studies showed a low antibody level against it. Ansari showed 3% positivity to PRP in 194 children under six years in Khoramabad (7); Jahromi and Rahmanian (8) determined the anti-HibIgG antibody (anti-PRP) level in 386 children aged 5 years or younger in the south of Iran. The proportion of natural immunity was 64.9% among 12-month-old children and 95.2% in 49-60-month-old children ($P < 0.001$) (8). This high rate of exposure indicted the emergent need for introducing the Hib vaccine to Iranian vaccination program. In IR Iran, Hib vaccination has started since 2014 in combination with diphtheria, pertussis, tetanus, and hepatitis B, as a pentavalent vaccine. This vaccine is prescribed in three doses at 2, 4, and 6 months of age in Iranian children. A vaccine effi-

cacy surveillance is needed to assess the protection rate of Iranian vaccinated children (9).

2. Objectives

This study aimed to determine the vaccine antibody response in Iranian one-year-old children after three-dose vaccination at 2, 4, and 6 months of age.

3. Methods

The target population of this study was healthy children attending health care centers in Karaj for the routine vaccination. Karaj is the capital of Alborz Province, Iran. The population of the city is 1.96 million based on the 2011 census. Karaj, after Tehran, Mashhad, and Isfahan is the fourth largest city in Iran. We estimated the immunogenicity prevalence rate as 80% and the clinically worthwhile effect size to detect (d) as 4%; with the calculation of the design effect, the sample size was determined. The sampling method was a cluster sampling. First, the 12 restricts in Karaj were listed to select six restricts; then, three centers were selected from each restrict randomly. Using the random sampling method, 28 cases were sampled from each center.

3.1. Vaccine

The vaccine used since 2014 in Iran is Pentavac that utilizes S11 Q-VACS II Q-VAC supplied by the Serum Institute of India Ltd. It is a pentavalent vaccine consisted of diphtheria toxoid, tetanus toxoid, killed *Bordetella pertussis* bacilli, and hepatitis B surface antigen adsorbed on an aluminum gel and suspended in isotonic sodium chloride solution. HBsAg was generated in the *Hansenula polymorpha* cells and purified through several chemical steps using recombinant DNA procedures. The preservative added is thiomersal. The vaccine meets the requirements of I.P. when tested by the methods outlined in I.P. Polysaccharide capsule of *H. influenzae* type B strain was used for vaccine Hib polysaccharide that was coupled to tetanus toxoid after activation. Each dose of the vaccine (0.5 mL) contains diphtheria toxoid 20 Lf to 30 Lf tetanus toxoid 5 to 25 Lf B pertussis (whole cell), 4 IU HBsAg (rDNA), 10 mcg purified capsular polysaccharide (PRP), 10 mcg tetanus toxoid (carrier protein) 19 to 33 mcg +++ Adsorbed on aluminum phosphate, Al 1.25 mg preservative: Thiomersal 0.005% (Serum Institute of INDIA vaccination brochure).

3.2. Antibody Measurement

Antibody measurement was established by IBL International GmbH, Germany Kit, measuring the serum IgG antibody against capsular polyribosylribitol phosphate (PRP) polysaccharide antigen by enzyme-linked immunosorbent assay (ELISA), 0.04 IU/ML sensitivity. The calibrators were correlated to Int Standard NIBSC96/536 (formerly WHO 1983). The results were expressed as micrograms of AntiPRP antibody per milliliter of the serum. Protective antibody concentrations (short-term and long-term protective thresholds) were $> 0.15 \mu\text{g/mL}$ and $> 1.0 \mu\text{g/mL}$, respectively. Anti-PRP antibody concentrations in serum were determined by using a standard protocol (10, 11).

3.3. Study Design

Each case had one blood sampling. Inclusion criteria were healthy one-year-old children with a history of complete vaccination. Exclusion criteria were a history of blood transfusion and IVIG reception three months ago and a history of congenital and acquired immunodeficiency. Each patient had a checklist for demographic data and IgG antibody report. Vaccine efficacy was measured by 95% CI. The logistic regression was used for demographic data and vaccine efficacy and quantitative variables were shown by mean and standard deviation.

3.4. Ethics

This study had an ethical approval from the university research council and the ethics in research committee. The permission was obtained from health officials to enter the health centers in Karaj (Ethical code= Abzums.rec.1394.70). After a description of the study objectives to parents, everybody who wanted to enter the study signed an informed consent form and sampling was performed for the children.

4. Results

500 one-year-old children attending the health centers for MMR vaccination entered the study. 51% were female and 49% were male. 98.6% of the children cared at home and 1.4% at child care centers. 23.8% of the cases had parents with a history of cigarette smoking. 27.7% of the cases had a history of more than one episode of respiratory infections in a month (frequent URI). 84.4% of the cases were completely breastfed. From among 500 cases, 41.2% (CI: 36.89 - 45.51) had anti-Hib antibody between 0.5 and 1 microgram per milliliter (short-lived immunity) and 57.4% (CI: 53.07 - 61.73) had antibody equal to or more than

one microliter per milliliter (efficient or long-lived immunity). Six cases had an antibody level of less than 0.15 microgram per milliliter. GMT titer against H flu type B was 6.92 (CI: 6.76 - 7.08). This measurement shows the mean log of each antibody measurement and indicates more accurate measures compared to simple mean in antibody measurement. There was no significant relationship between the response to vaccine and demographic parameters such as weight and height at the time of sampling, birth weight, type of milk used in the first year of life, cigarette smoking of parents, having siblings more than one-years-old, parents education, history of recurrent respiratory infections, and daycare attendance (Table 1).

5. Discussion

The *Haemophilus influenzae* vaccine is being used in many countries all over the world. Its efficacy and effectiveness were investigated by the measurement of anti-HIB geometric mean of titer, HIB throat colonization population, and the rate of invasive Hib infection in children. Although vaccination in industrialized countries reduced the prevalence of invasive diseases, the vaccination cost and unclear data about disease burden in Asia are responsible for the delayed adoption of the vaccine in these countries (12, 13). The WHO estimates 92% HIB vaccination coverage in developed countries eligible population in comparison with 42% in developing countries (14). Today, HIB vaccination is increasingly used in underdeveloped countries. For example, Mali as an underdeveloped and landlocked country in West Africa started HIB vaccination in 2005 in a stepwise manner. The antibody was higher among vaccinated children than in an unvaccinated group and its protective capability persisted through 2 years of age (15). One important marker for the detection of vaccine efficacy is a serologic study on Hib antibody in different time limits after vaccination. In a study in Saudi Arabia (1992) on 17 to 19-month-old children after Hib (PRP-D) vaccination, the antibody was measured prior and one to two months after vaccination. Prior to vaccination, in 77% of the cases, antibody value was measured below the level of short-term protection ($\geq 0.15 \mu\text{g/mL}$) and 88% were below the level of long-term protection ($\geq 1 \mu\text{g/mL}$). After reception of one dose of PRP-D, 100% of the cases developed short-term protection ($\geq 0.15 \mu\text{g/mL}$) and 85% had long-term protection ($\geq 1 \mu\text{g/mL}$) (16). In a study in 117 Brazilian infants (2002), the anti-Hib antibody was determined at 3, 6, and 15 months after PRP-T vaccination, which was injected at three and five months of age. GMT at 15 months was $4.45 \mu\text{g/mL}$ (17). In

a study in Turkey in our neighborhood in 2007, the anti-PRP antibody raised significantly in vaccinated children (100%) and 68% of the non-vaccinated children had an antibody level of $> 0.15 \mu\text{g/mL}$ against Hflu. Oropharyngeal colonization was significantly higher in the non-vaccinated group (18). In areas where the Hib disease burden is not well characterized because of lower laboratory detection and identification of organisms, understanding of the epidemiology of Hib disease is necessary to estimate the value of Hib conjugate vaccine (19). In our study, 41.2% of the children (95% CI: 36.89% - 45.51%) had anti-Hib IgG titer as 0.15 to $1 \mu\text{g/mL}$ (short-term protection) and 57.4% (95% CI: 53.07% - 61.73%) of the children had anti-Hib IgG titer equal to or greater than $1 \mu\text{g/mL}$ (long-term protection). The low rate of long-term immunity in this study indicates the possibility of declined antibody level over the time, so a booster dose may be needed. Unfortunately, there are a few studies about Iranian children antibody response after Hib vaccination. On the other hand, since the conjugate vaccines can promote T-dependent immunity, in organism encountering, a secondary response may occur due to immune memory. This occurred in Finish infant whose PRP-D vaccine demonstrated 94% efficacy, despite 34% anti-PRP antibody levels above $1 \mu\text{g/mL}$ (20, 21). Therefore, investigation of invasive Hib disease burden and rate of its throat colonization may show the possibility of herd immunity to protect children with less than optimal antibody level as a better index for vaccine efficacy. The Iranian Hib vaccination program includes three primary 3p+0. This type of vaccination has no booster at 15-18 months. Any combination of 2p+1, 3p+0, or 3p+1 schedule of Hib conjugate vaccine has no inferiority to another type. The selection of each program is based on the epidemiology of the infectious organism and is individualized (22). GMT titer against H flu type B in this study was 6.92 (CI: 6.76 - 7.08), six cases had a level of less than $0.15 \mu\text{g/mL}$, and approximately 50% of the children had a level of less than $1 \mu\text{g/mL}$. This study shows the need for antibody assessment in two-year-old Iranian children. Antibody response below the expected level warns to do a further detailed study of antibody level in our children.

5.1. Conclusions

Based on the results, we are not sure of vaccine failure because GMT result was not at a very low level. The introduction of the HIB vaccine has positive effects on the immunity of children under 2 years old. Future study on antibody at higher ages and determination of throat colonization and invasive HIB infection pattern are necessary to es-

Table 1. Short and Long-Lived Immunity Estimation in 500 One-Year-Old Children Admitted to Karaj Health Centers (IR Iran) in 2016

Variables	Short-Lived Immunity ($\geq 0.15 < 1$)	Long-Lived Immunity ≥ 1	Total	P-Value
Weight (g)	9577 (1112)	9645 (1103)	-	0.5
Height (cm)	75.93 (3.83)	76.15 (3.27)	-	0.49
Sex				
Male	108 (44.3)	136 (55.7)	244	0.38
Female	101 (40.4)	149 (59.6)	250	
Sibling numbers				
< 2	173 (40.6)	253 (59.4)	426	0.05
≥ 2	36 (51.9)	32 (47.1)	68	
Academic	40 (35.4)	73 (64.6)	113	
Place of child care				
House	206 (42.3)	281 (57.7)	487	0.97
Kindergarten	3 (42.9)	4 (57.1)	7	
Parent smoking				
Yes	48(40.3)	71(59.7)	119	0.61
No	161 (42.9)	214 (57.1)	375	
Exclusive breastfeeding				
Yes	180 (43.3)	236 (56.7)	416	0.31
No	29 (37.2)	49 (62.8)	78	
No	11 (28.9)	27 (71.1)	38	
No	149 (41.5)	210 (58.5)	359	
Birth weight (g)				
≤ 2500	20 (54.1)	17 (45.9)	37	0.27
$> 2500 < 4000$	184 (41.2)	263 (58.8)	447	
≥ 4000	5 (50.0)	5 (50.0)	10	

estimate the conclusive effect of this vaccine on the Iranian population.

Acknowledgments

This is to give our special thanks to Shahid Bahonar Hospital Clinical Research Development Unit (Alborz University of Medical Sciences) and Fardis Medical Laboratory (KARAJ) for their comprehensive cooperation in this study.

References

- Peltola H. Worldwide Haemophilus influenzae type B disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev.* 2000;**13**(2):302-17. [PubMed: 10756001]. [PubMed Central: PMC100154].
- Feikin DR, Nelson CB, Watt JP, Mohsni E, Wenger JD, Levine OS. Rapid assessment tool for Haemophilus influenzae type B disease in developing countries. *Emerg Infect Dis.* 2004;**10**(7):1270-6.

doi: 10.3201/eid1007.030737. [PubMed: 15324548]. [PubMed Central: PMC3323330].

- Wenger JD, DiFabio JL, Landaverde JM, Levine OS, Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four "newly adopting" countries. *Vaccine.* 1999;**18**(7-8):736-42.
- Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type B in children younger than 5 years: global estimates. *Lancet.* 2009;**374**(9693):903-11. doi: 10.1016/S0140-6736(09)61203-4.
- World Health Organization. WHO position paper on Haemophilus influenzae type B conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record. *Wkly Epidemiol Rec.* 2006;**81**(47):445-52. [PubMed: 17124755].
- World Health Organization. *WHO Factsheet.* 2016. Available from: <http://www.who.int/mediacentre/factsheets/fs378/en/>.
- Ansari N, Porrostami K, Farzaneh F, Zibai M. [Serologic investigation of Hflv B in children under six years old (Khoramabad-I.R. Iran)]. *Sci Res J Alborz Med Univ.* 2015;**4**(2):84-90. Persian.
- Jahromi AS, Rahmanian K. Natural immunity to hemophilus influenzae type B in children, south of Iran: need for vaccination. *Pak J Biol Sci.* 2012;**15**(3):160-3. [PubMed: 22866548].

9. [No Authors Listed]. Schedule and guideline of immunization, approved by National Immunization Technical Advisory Group. *I.R. Iran*. 2015.
10. Booy R, Taylor SA, Dobson SR, Isaacs D, Sleight G, Aitken S, et al. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. *Arch Disease Childhood*. 1992;**67**:475-478.
11. Kelly DF, Moxon ER, Yu LM, Pollard AJ. Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type B immunization of infants in the United Kingdom. *Clin Vaccine Immunol*. 2009;**16**(2):246-52. doi: [10.1128/CVI.00023-08](https://doi.org/10.1128/CVI.00023-08). [PubMed: [18784340](https://pubmed.ncbi.nlm.nih.gov/18784340/)]. [PubMed Central: [PMC2643546](https://pubmed.ncbi.nlm.nih.gov/PMC2643546/)].
12. Peltola H. Spectrum and burden of severe Haemophilus influenzae type B diseases in Asia. *Bull World Health Organ*. 1999;**77**(11):878-87. [PubMed: [10612883](https://pubmed.ncbi.nlm.nih.gov/10612883/)]. [PubMed Central: [PMC2557760](https://pubmed.ncbi.nlm.nih.gov/PMC2557760/)].
13. Shetty S, Cohen AL, Edmond K, Ojo L, Loo J, O'Loughlin R, et al. A systematic review and critical evaluation of invasive Haemophilus influenzae type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. *Pediatr Infect Dis J*. 2010;**29**(7):653-61. doi: [10.1097/INF.0b013e3181d3ce19](https://doi.org/10.1097/INF.0b013e3181d3ce19). [PubMed: [20168264](https://pubmed.ncbi.nlm.nih.gov/20168264/)].
14. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type B conjugate vaccine use and effectiveness. *Lancet Infect Dis*. 2008;**8**(7):435-43. doi: [10.1016/S1473-3099\(08\)70152-X](https://doi.org/10.1016/S1473-3099(08)70152-X). [PubMed: [18582836](https://pubmed.ncbi.nlm.nih.gov/18582836/)].
15. Hutter J, Pasetti MF, Levine MM, Tapia MD, Sow SO, Sanogo D. Naturally acquired and conjugate vaccine-induced antibody to haemophilus influenzae type B (hib) polysaccharide in malian children: serological assessment of the hib immunization program in Mali. *Am J Trop Med Hyg*. 2012;**86**(6):1026-31. doi: [10.4269/ajtmh.2012.11-0807](https://doi.org/10.4269/ajtmh.2012.11-0807).
16. Frayha HH, Shaheen H, Ganelin RS, Kattan HA, Tufenkeji HT, Krotzer S, et al. Clinical and serologic responses of saudi children to hemophilus influenzae type B capsular polysaccharide diphtheria toxoid conjugate vaccine. *Ann Saudi Med*. 1993;**13**(3):215-21. doi: [10.5144/0256-4947.1993.215](https://doi.org/10.5144/0256-4947.1993.215).
17. Guimaraes T, Cereda RF, Bianchin PJ, Nagao AT, Sampaio MC, Mendonca JS. Antibody response to Haemophilus influenzae type B tetanus conjugate vaccine with two doses given at 3 and 5 months of age. *Int J Infect Dis*. 2002;**6**(2):113-7. [PubMed: [12121598](https://pubmed.ncbi.nlm.nih.gov/12121598/)].
18. Arvas A, Gur E, Bahar H, Torun MM, Demirci M, Aslan M, et al. Haemophilus influenzae type B antibodies in vaccinated and non-vaccinated children. *Pediatr Int*. 2008;**50**(4):469-73. doi: [10.1111/j.1442-200X.2008.02591.x](https://doi.org/10.1111/j.1442-200X.2008.02591.x). [PubMed: [19143969](https://pubmed.ncbi.nlm.nih.gov/19143969/)].
19. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting. *The Journal of Pediatrics*. 2003;**143**(6):163-87. doi: [10.1067/s0022-3476\(03\)00576-6](https://doi.org/10.1067/s0022-3476(03)00576-6).
20. Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type B (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. *Clin Vaccine Immunol*. 2007;**14**(10):1328-33. doi: [10.1128/CVI.00191-07](https://doi.org/10.1128/CVI.00191-07). [PubMed: [17699835](https://pubmed.ncbi.nlm.nih.gov/17699835/)]. [PubMed Central: [PMC2168123](https://pubmed.ncbi.nlm.nih.gov/PMC2168123/)].
21. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type B disease. *N Engl J Med*. 1990;**323**(20):1381-7. doi: [10.1056/NEJM19901153232004](https://doi.org/10.1056/NEJM19901153232004). [PubMed: [2233904](https://pubmed.ncbi.nlm.nih.gov/2233904/)].
22. Low N, Redmond SM, Rutjes AWS, Martínez-González NA, Egger M, di Nisio M, et al. Comparing Haemophilus influenzae type B conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials. *Pediatr Infect Dis J*. 2013;**32**(11):1245-56.